1st Floor, Unex House
132-134 Hills Road
Tel: 44-0-1223 341150
162 articles with Avita Medical
Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st
New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
AVITA Medical (ASX: AVH, OTCQX: AVMXY), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s Investigational Device Exemption (IDE) application to conduct a pivotal trial evaluating the safety and effectiveness of the RECELL® Autologous Cell Harvesting Device (RECELL® System) in combination with meshed autografting for the treatment of acute full-thickness skin defect
AVITA Medical, a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019.
AVITA Medical, a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 30 June 2019, the fourth quarter of its fiscal 2019.
RECELL® System Feasibility Study Results for Treatment of Diabetic Foot Ulcers Presented at 11th Annual Congress of the Japanese Society of Limb Salvage & Podiatric Medicine
Innovative regenerative technology using patients’ own skin cells significantly reduced size of wounds caused by diabetic foot ulcers in all patients
AVITA Medical Announces RECELL® System Preliminary Data Focused on Vitiligo and Facial Acne Scars at the 24th Annual World Congress of Dermatology
Abstracts Showcase Research on Potential Use of RECELL® System in Regenerative Dermatology
Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System
AVITA Medical announced that the health economic model of the U.S. burn care pathway, developed in collaboration with Biomedical Advanced Research and Development Authority (BARDA) and IQVIA, has been published in the peer-reviewed journal, Advances in Therapy.
AVITA Medica announced that Dale A. Sander is resigning as Chief Financial Officer (CFO) to spend more time with his family on the east coast, effective immediately.
AVITA Medical, a global regenerative medicine company, announced that management will present at the RBC Capital Markets 2019 Healthcare Conference in New York.
Strong U.S. product sales of A$2.2 million for third quarter of Fiscal 2019 were double second quarter sales
In September 2018 a leap forward in treating burn victims was made with the approval of Avita Medical's RECELL Autologous Cell Harvesting Device. The Food and Drug Administration (FDA) green lit the California-based company’s burn treatment device that uses a small amount of a patient’s own skin...
AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients
Professor Fiona Wood, co-inventor of the RECELL System, described her experience treating more than 3,500 patients using RECELL and resulting benefits, including reduced time to healing and decreased length of hospitalization
AVITA Medical RECELL® System Health Economic Data Project USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care
Additional data presented at ABA Annual meeting include results demonstrating that donor sites treated using the RECELL System could be reharvested in as little as seven days after treatment
AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston.
AVITA Medical Announces Ten RECELL® System Presentations at the American Burn Association (ABA) Annual Meeting
Presentation describing treatment of pediatric patients with RECELL System selected as “Best of the Best Abstract”
Avita Medical Announces Collaboration with COSMOTEC, an M3 Group Company, to Commercialize the RECELL® System in Japan
COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan
Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance
AVITA Medical, a global regenerative medicine company, announced that it filed with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018.
Pre-launch U.S. product sales of A$1.1 million in second quarter